Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Cephalon Inc has reached an agreement for the exclusive option to develop and commercialize products based on K252a, a compound being evaluated by Bio3 Research and Creabilis Therapeutics.
Subscribe to our email newsletter
K252a is a research compound being evaluated by the company’s for its potential to topically treat psoriasis, and for potential use in the prevention and treatment of restenosis.
Creabilis Therapeutics owns patent applications covering K252a-based products for the treatment of psoriasis, and co-owns with Bio3 Research a patent covering the use of the compound to prevent and treat restenosis and other cardiovascular disorders. Cephalon has proprietary rights in certain production processes for the compound.
“We are delighted to have entered into this agreement with Cephalon, and we believe it is a great opportunity for our company to accelerate the ongoing development process at Creabilis Therapeutics,” said Francesco Paolo Pilato, president and CEO of Bio3 Research.